This approval expands Blenrep’s global footprint into a major market, reinforcing its clinical value and commercial potential. Traders should monitor upcoming sales figures in GSK’s next quarterly report for early revenue traction in China, which could support valuation upside in oncology-focused segments.
Price Chart
Executive Summary
GSK plc announced that its drug Blenrep (belantamab mafodotin) has been approved in China for use in combination with bortezomib and dexamethasone to treat adults with relapsed or refractory multiple myeloma who have received at least one prior therapy. The approval is based on the DREAMM-7 phase III trial, which demonstrated a 42% reduction in risk of death and nearly tripled median progression-free survival compared to a standard-of-care regimen.
Key Facts
- Blenrep approved in China for 2L+ relapsed/refractory multiple myeloma in combination with bortezomib and dexamethasone.
- Approval supported by DREAMM-7 phase III trial showing 42% reduction in risk of death (OS HR 0.58) and median PFS of 36.6 months vs. 13.4 months for comparator.
- Blenrep is the only anti-BCMA antibody-drug conjugate approved in China for this indication and is fully outpatient-administered.
- The drug had previously received Breakthrough Therapy Designation and priority review in China.
Financial Impact
Potential for meaningful revenue growth in a high-need oncology market; China sees ~30,000 new multiple myeloma cases annually.
Risk Factors
- Competition from other anti-BCMA therapies in development.
- Potential safety concerns related to ocular side effects, though discontinuation rates were low (≤9%).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-003693 |
| Document: 0001654954-26-003693-index-headers.html | 0001654954-26-003693 |
| Document: 0001654954-26-003693-index.html | 0001654954-26-003693 |
| Document: 0001654954-26-003693.txt | 0001654954-26-003693 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 10, 2026 19w ago | 6-K | $25.12 $25.25 | ▲ +0.52% | ▼ −1.62% | $26.12 (+3.98%) |
Jun 9, 2026 19w ago | 6-K | $24.66 $25.50 | ▲ +3.41% | ▲ +1.60% | $26.12 (+5.92%) |
Jun 9, 2026 20w ago | 6-K | $24.66 $25.50 | ▲ +3.41% | ▲ +1.60% | $26.12 (+5.92%) |
Jun 1, 2026 21w ago | 6-K | $24.25 $24.66 | ▲ +1.69% | ▲ +4.44% | $26.12 (+7.71%) |
Jun 1, 2026 21w ago | 6-K | $24.25 $24.66 | ▲ +1.69% | ▲ +4.44% | $26.12 (+7.71%) |
May 28, 2026 21w ago | 6-K | $24.58 $24.66 | ▲ +0.33% | ▲ +0.01% | $26.12 (+6.27%) |
May 27, 2026 21w ago | 6-K | $25.57 $23.94 | ▼ −6.37% | ▼ −7.58% | $26.12 (+2.15%) |
May 26, 2026 22w ago | 6-K | $25.50 $24.25 | ▼ −4.90% | ▼ −5.99% | $26.12 (+2.43%) |
May 26, 2026 22w ago | 6-K | $25.50 $24.25 | ▼ −4.90% | ▼ −5.99% | $26.12 (+2.43%) |
May 22, 2026 22w ago | 6-K | $26.00 $24.25 | ▼ −6.73% | ▼ −8.39% | $26.12 (+0.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers